Hemos leído sobre ... Esclerodermia

Última actualización: 11 abril 2017

MARZO 2017
  • Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.
    Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
    Arthritis Rheumatol. 2017 Apr 4. doi: 10.1002/art.40114.
  • Boulos D, Ngian GS, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J.
    Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Int J Rheum Dis. 2017 Mar 24. doi: 10.1111/1756-185X.13035.
  • Nevskaya T, Baron M, Pope JE; Canadian Scleroderma Research Group.
    Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Rheumatology (Oxford). 2017 Mar 17. doi: 10.1093/rheumatology/kex015.

ENERO 2017
  • Eutsler EP, Horton DB, Epelman M, Finkel T, Averill LW.
    Musculoskeletal MRI findings of juvenile localized scleroderma.
    Pediatr Radiol. 2017 Jan 14. doi: 10.1007/s00247-016-3765-x. [Epub ahead of print]
  • Garcia-Romero MT, Randhawa HK, Laxer R, Pope E.
    The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity.
    Int J Dermatol. 2017 Jan;56(1):63-67. doi: 10.1111/ijd.13452.
  • Hetlevik SO, Flatø B, Rygg M, Nordal EB, Brunborg C, Hetland H, Lilleby V.
    Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study.
    Ann Rheum Dis. 2017 Jan;76(1):159-165. doi: 10.1136/annrheumdis-2016-209522. Epub 2016 Jun 9.

  • Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.
    The European Scleroderma Trials and Research group (EUSTAR) task forcé for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.
    Ann Rheum Dis. 2017 Jan;76(1):270-276.

  • Silva M, Ribeiro R, Oliveira J.
    Pseudoainhum in Systemic Sclerosis.
    J Rheumatol. 2016 Nov;43(11):2076.
  • Stevens AM, Kanaan SB, Torok KS, Medsger TA, Mayes MD, Reveille JD, Klein-Gitelman M, Reed AM, Lee T, Li SC, Henstorf G, Luu C, Aydelotte T, Lee Nelson J.
    HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis.
    Arthritis Rheumatol. 2016 Nov;68(11):2772-2777.
  • Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, Cutolo M.
    Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
    J Rheumatol. 2016 Nov;43(11):2033-2041.

  • Pain CE, Constantin T, Toplak N, Moll M, Iking-Konert C, Piotto DP, Aktay Ayaz N, Nemcova D, Hoeger PH, Cutolo M, Smith V, Foeldvari I; Paediatric Rheumatology European Society (PRES) Juvenile Scleroderma Working Group.
    Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring
    Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):200-206.
  • Zulian F, Balzarin M, Birolo C.
    Recent advances in the management of juvenile systemic sclerosis
    Expert Rev Clin Immunol. 2016 Oct 3

  • Cabrera N, Duquesne A, Desjonquères M, Larbre JP, Lega JC, Fabien N, Belot A.
    Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children.
    RMD Open. 2016 Sep 15;2(2):e000271.
  • Valões CC, Novak GV, Brunelli JB, Kozu KT, Toma RK, Silva CA.
    Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations?
    Rev Bras Reumatol. 2016 Sep 17.

  • Woodworth TG, Suliman YA, Furst DE, Clements P.
    Scleroderma renal crisis and renal involvement in systemic sclerosis.
    Nat Rev Nephrol. 2016 Sep 19. doi: 10.1038/nrneph.2016.124. [Epub ahead of print].
  • Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.
    The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.
    Ann Rheum Dis. 2016 Sep 12. pii: annrheumdis-2016-209768. doi: 10.1136/annrheumdis-2016-209768. [Epub ahead of print]
  • Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ.
    Frontiers of antifibrotic therapy in systemic sclerosis.
    Arthritis Rheumatol. 2016 Sep 16. doi: 10.1002/art.39865. [Epub ahead of print]
  • Crowell MD, Umar SB, Griffing WL, DiBaise JK, Lacy BE, Vela MF.
    Esophageal Motor Abnormalities in Patients with Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life.
    Clin Gastroenterol Hepatol. 2016 Sep 6. pii: S1542-3565(16)30615-2. doi: 10.1016/j.cgh.2016.08.034. [Epub ahead of print]
  • Baron M, Pope J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larché M, Abu-Hakima M, Rodriguez-Reyna TS, Cabral-Castaneda AR, Fritzler MJ, Wang M, Hudson M.
    Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study.
    Rheumatology (Oxford). 2016 Sep 4. pii: kew313. [Epub ahead of print]
  • Fotis L, Baszis KW, White AJ, French AR.
    Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
    J Rheumatol. 2016 Sep;43(9):1768-9.
  • Sakkas LI.
    Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Drug Des Devel Ther. 2016 Aug 29;10:2723-8.
  • Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S.
    Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity.
    Springerplus. 2016 Aug 23;5(1):1401.

JUNIO 2016
  • Sanges S, Desauw C, de Groote P, Fertin M, Lamblin N, Bervar JF, Hatron PY, Hachulla E, Launay D.
    Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report.
    Rev Med Interne. 2016 Jun 28. pii: S0248-8663(16)30410-6. doi: 10.1016/j.revmed.2016.05.020

MAYO 2016

ABRIL 2016

MARZO 2016
  • Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors.
    Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
    Ann Rheum Dis. 2016 Mar 25. pii: annrheumdis-2015-208024. doi: 10.1136/annrheumdis-2015-208024. [Epub ahead of print]
  • Ligon C, Hummers LK.
    Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.
    Curr Rheumatol Rep. 2016 Mar;18(3):17. doi: 10.1007/s11926-016-0565-0.
  • Gigante A, Barbano B, Barilaro G, Quarta S, Gasperini ML, Di Mario F, Romaniello A, Amoroso A, Cianci R, Rosato E.
    Serum uric acid as a marker of microvascular damage in systemic sclerosis patients.
    Microvasc Res. 2016 Mar 18. pii: S0026-2862(16)30021-8. doi: 10.1016/j.mvr.2016.03.007. [Epub ahead of print]


  • Stella Aslibekyan, Vincent A. Laufer, Donna K. Arnett and S. Louis Bridges
    A novel genetic association with systemic sclerosis: The utility of whole exome sequencing in autoimmune disease
    Arthritis & Rheumatology. DOI: 10.1002/art.39451
  • Athanasios Mavropoulos, Theodora Simopoulou, Areti Varna, Christos Liaskos, Christina Katsiari, Dimitrios P. Bogdanos and Lazaros I. Sakkas
    B regulatory cells are decreased and functionally impaired in patients with systemic sclerosis

    Arthritis & Rheumatology DOI: 10.1002/art.39437
  • Alexandre TJ Maria, Karine Toupet, Claire Bony, Nelly Pirot, Marie-Catherine Vozenin, Benoît Petit, Pascal Roger, Frédéric Batteux, Alain Le Quellec, Christian Jorgensen, Danièle Noël and Philippe Guilpain
    Anti-fibrotic, anti-oxidant and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis

    Arthritis & Rheumatology. DOI: 10.1002/art.39477
  • Ramos, Paula S; Silver, Richard M; Feghali-Bostwick, Carol A
    Genetics of systemic sclerosis: recent advances

    Current Opinion in Rheumatology:
    November 2015 - Volume 27 - Issue 6 - p 521–529
    doi: 10.1097/BOR.0000000000000214
  • Lara Bossini-Castillo, , Elena López-Isac, Javier Martín
    Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways
    Journal of Autoimmunity
    Volume 64, November 2015, Pages 53–65

  • Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL
    Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.
    Rheumatology (Oxford). 2015 Nov;54(11):2015-24. doi: 10.1093/rheumatology/kev201.

  • Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, García-Hernández FJ, Castillo-Palma MJ, Sánchez-Román J, Callejas-Rubio JL, Ortego-Centeno N, Egurbide-Arberas MV, Trapiellla-Martínez L, Caminal-Montero L, Sáez-Comet L, Velilla-Marco J, Camps-García MT, de Ramón-Garrido E, Esteban-Marcos EM, Pallarés-Ferreres L, Navarrete-Navarrete N, Vargas-Hitos JA, Torre RG, Salvador-Cervello G, Rios-Blanco JJ, Vilardell-Tarrés M; Spanish Scleroderma Study Group (SSSG), Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI).
    Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death.
    Medicine (Baltimore). 2015 Oct;94(43):e1728.
  • Avouac J, Riemekasten G, Meune C, Ruiz B, Kahan A, Allanore Y.
    Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis
    J Rheumatol October 2015;42(10):1801-7; doi:10.3899/jrheum.150061

  • Torok KS, Kurzinski K, Kelsey C, Yabes J, Magee K, Vallejo AN, Medsger T Jr, Feghali-Bostwick CA.
    Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.
    Semin Arthritis Rheum. 2015 Jun 17. pii:S0049-0172(15)00144-4.doi:10.1016/j.semarthrit.2015.06.006. EPUB ahead of print]
  • Poff S, Li SC, Kelsey CE, Foeldvari I, Torok KS.
    Durometry as an Outcome Measure in Juvenile Localized Scleroderma.
    Br J Dermatol. 2015 Aug 24. doi:10.1111/bjd.14103. EPUB ahead of print]
  • Ingegnoli F, Boracchi P, Gualtierotti R, Smith V, Cutolo M, Foeldvari I; EUSTAR co-authors.
    A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.
    Microvasc Res. 2015 Aug 4;102:19-24. doi:10.1016/j.mvr.2015.07.007. EPUB ahead of print]

JUNIO 2015
  • Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL.
    Consensus best practice pathway of the UK Systemic Sclerosis Study Group: digital vasculopathy in systemic sclerosis.
    Rheumatology (Oxford). 2015 Jun 26. pii: kev201. [Epub ahead of print]

MAYO 2015
  • Eric Hachulla, Pierre-Yves Hatron, Patrick Carpentier, Christian Agard, Emmanuel Chatelus, Patrick Jego, et al, on behalf of the SEDUCE study group.
    Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
    Ann Rheum Dis doi:10.1136/annrheumdis-2014-207001 [Published on line: 20 may 2015]
  • Britta Maurer, Nicole Graf, Beat A Michel, Ulf Müller-Ladner, László Czirják, Christopher P Denton, et al, EUSTAR co-authors
    Extended report: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
    Ann Rheum Dis 2015;74:1124-1131 doi:10.1136/annrheumdis-2014-205226
  • Suzana Jordan, Jörg H W Distler, Britta Maurer, Dörte Huscher, Jacob M van Laar, Yannick Allanore, et al on behalf of the EUSTAR Rituximab study group
    Extended report: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Ann Rheum Dis 2015;74:1188-1194 doi:10.1136/annrheumdis-2013-204522
  • Young, Amber; Khanna, Dinesh
    Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014
    Current Opinion in Rheumatology, May 2015, Vol 27, Issue 3
  • Fiona M. McQueen and Kamal Solanki
    Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
    Rheumatology (2015) 54 (5): 757-767 doi:10.1093/rheumatology/keu463

ABRIL 2015

MARZO 2015

    • Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM.
      Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease.
      Br J Dermatol. 2015 Mar;172(3):722-8. doi: 10.1111/bjd.13514
    • Young A, Khanna D.
      Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
      Curr Opin Rheumatol. 2015 May;27(3):241-8. doi: 10.1097/BOR
    • Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JHW, Fierlbeck G et al
      Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
      Ann Rheum Dis 2015;74:730-737. doi:10.1136/annrheumdis-2013-204487
    • Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS.
      Serum heparanase levels: A protective marker against digital ulcers in patients with systemic sclerosis.
      J Dermatol. 2015 Mar 21. doi: 10.1111/1346-8138.12842. [Epub ahead of print]
    • Foeldvari I.
      Update on juvenile systemic sclerosis
      Curr Rheumatol Rep. 2015 Mar;17(3):491. doi: 10.1007/s11926-014-0491-y.
    • Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL.
      Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.
      Rheumatology (Oxford). 2015 Mar 9. pii: kev002. [Epub ahead of print]
    • Hughes M, Moore T, O'Leary N, Tracey A, Ennis H, Dinsdale G, Murray A, Roberts C, Herrick AL.
      A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders.
      Rheumatology (Oxford). 2015 Mar 6. pii: keu533. [Epub ahead of print]


  • Gerhold K, Becker MO.
    Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications.
    Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-183-8.

  • Falcini F, Rigante D, Candelli M, Martini G, Corona F, Petaccia A, La Torre F, Raffaele CG, Matucci Cerinic M.
    Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon.
    Clin Rheumatol. 2014 Nov 28. [Epub ahead of print]
  • Polcari I, Moon A, Mathes EF, Gilmore ES, Paller AS.
    Headaches as a Presenting Symptom of Linear Morphea en Coup de Sabre.
    Pediatrics. 2014 Nov 17. pii: peds.2014-0019. [Epub ahead of print]
  • Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM.
    Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease.
    Br J Dermatol. 2014 Nov 7 [Epub ahead of print]
  • Condie D, Grabell D, Jacobe H.
    Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort.
    Arthritis Rheumatol. 2014 Dec;66(12):3496-504.
  • Taniguchi T, Asano Y, Tamaki Z, Akamata K, Aozasa N, Noda S, Takahashi T, Ichimura Y, Toyama T, Sugita M, Sumida H, Kuwano Y, Miyazaki M, Yanaba K, Sato S.
    Histological features of localized scleroderma 'en coup de sabre': a study of 16 cases.
    J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1805-10.
  • Jackson CT, Maibach HI.
    Localized scleroderma variants: pharmacologic implications.
    J Dermatolog Treat. 2014 Dec;25(6):529-31.
  • Hong BY1, Giang R, Mbuagbaw L, Larche M, Thabane L
    Factors associated with development of gastrointestinal problems in patients with scleroderma: a protocol for a systematic review.
    Syst Rev. 2014 Oct 13;3(1):115. doi: 10.1186/2046-4053-3-115.
  • Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt O, Molberg O.
    Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease.
    J Rheumatol. 2014 Oct 1. pii: jrheum.140047. [Epub ahead of print]

  • Jacobe H, Ahn C, Arnett F, Reveille JD.
    Major histocompatibility complex (MHC) class I and II alleles which confer susceptibility or protection in the Morphea in Adults and Children (MAC) cohort.
    Arthritis Rheumatol. 2014 Sep 15. doi: 10.1002/art.38814. [Epub ahead of print]

  • van Bon L1, Cossu M1, Loof A2, Gohar F3, Wittkowski H3, Vonk M4, Roth J5, van den Berg W4, van Heerde W2, Broen JC6, Radstake TR6.
    Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker forsystemic sclerosis phenotype.
    Ann Rheum Dis. 2014 Aug;73(8):1585-9. doi: 10.1136/annrheumdis-2013-205013. Epub 2014 Apr 9.

JULIO 2014
  • Launay D, Savale L, Berezne A, Le Pavec J, Hachulla E, Mouthon L, Sitbon O, Lambert B, Gaudric M, Jais X, Stephan F, Hatron PY, Lamblin N, Vignaux O, Cottin V, Farge D, Wallaert B, Guillevin L, Simonneau G, Mercier O, Fadel E, Dartevelle P, Humbert M, Mussot S; On behalf of the Working Group on Heart/Lung transplantation in systemic sclerosis of the French Network on Pulmonary Hypertension.
    Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group.
    Presse Med. 2014 Jul 11. pii: S0755-4982(14)00311-X. doi: 10.1016/j.lpm.2014.01.020.
  • Saad Magalhães C, Fernandes Tde A, Fernandes TD, Resende LA.
    A cross-sectional electromyography assessment in linear sclerodermapatients.
    Pediatr Rheumatol Online J. 2014 Jul 12;12:27.

JUNIO 2014
  • Schicchi N, Valeri G, Moroncini G, Agliata G, Salvolini L, Gabrielli A, Giovagnoni A.
    Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance.
    Radiol Med. 2014 Jun 7. [Epub ahead of print]
  • Webber M, Natarajan A, Schreiber B, Sanjay P, Schwaiger J, Handler C, Coghlan G.
    136 Cardiac involvement in systemic sclerosis: strengths and limitations of cardiac magnetic resonance imaging.
    Heart. 2014 Jun;100 Suppl 3:A80. doi: 10.1136/heartjnl-2014-306118.136.

MAYO 2014
  • Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
    Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Int J Rheum Dis. 2014 May 26. doi: 10.1111/1756-185X.12399. [Epub ahead of print]
  • Hawley DP1, Pain CE2, Baildam EM2, Murphy R2, Taylor AE2, Foster HE3.
    United Kingdom survey of current management of juvenile localized scleroderma.
    Rheumatology (Oxford). 2014 May 21. pii: keu212. [Epub ahead of print]

MARZO 2014
  • Hatta Y1, Hasegawa M, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K.
    The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients.
    Mod Rheumatol. 2014 Mar;24(2):377-9. doi: 10.3109/14397595.2013.854073.

ENERO 2014
  • Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; on behalf of the EUSTAR Rituximab study group.
    Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Ann Rheum Dis. 2014 Jan 17. doi: 10.1136/annrheumdis-2013-204522. [Epub ahead of print]

  • Khanna D, Gladue H, Channick R et al.
    Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.
    Arthritis Rheum. 2013 Dec;65(12):3194-201. doi: 10.1002/art.38172

  • van den Hoogen F, Khanna D, Fransen J, Johnson SR et al.
    2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.
    Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098.



  • Gladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, Berrocal VJ, Avouac J, Meune C, Trivedi M, Khanna D.
    Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts.
    J Rheumatol. 2013 Aug 15. [Epub ahead of print]

ABRIL 2013

ENERO 2013
  • Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A.
    Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.
    Rheumatology (Oxford) 2013 Jan;52(1):143-54. doi: 10.1093/rheumatology/kes303. Epub 2012 Nov 22.
  • Schanz S, Henes J, Ulmer A, Kötter I, Fierlbeck G, Claussen CD, Horger M.
    Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms.
    Eur Radiol 2013 Jan;23(1):212-21. doi: 10.1007/s00330-012-2584-1.

  • La Torre F, Giorgia Martini G, Russo R, Katsicas MM, Corona F, Calcagno G, Falcini F, Vittadello F, Zulian F.
    A preliminary disease severity score for juvenile systemic sclerosis.
    Arthritis Rheum 2012 Dec; 64(12):4143-50. DOI: 10.1002/art.34652.

  • Caron M, Hudson M, Baron M, Nessim S, Steele R; Canadian Scleroderma Research Group.
    Longitudinal study of renal function in systemic sclerosis.
    J Rheumatol 2012 Sep;39(9):1829-34. doi: 10.3899/jrheum.111417

  • Li SC,Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S,Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.
    Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
    Arthritis Care Res (Hoboken) 2012 Aug;64(8):1175-85. doi: 10.1002/acr.21687.

Área de Socios